Citizens Financial Group Inc. RI Purchases 104,167 Shares of Pfizer Inc. (NYSE:PFE)

Citizens Financial Group Inc. RI raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 52.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 304,477 shares of the biopharmaceutical company's stock after purchasing an additional 104,167 shares during the quarter. Citizens Financial Group Inc. RI's holdings in Pfizer were worth $8,812,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. FAS Wealth Partners Inc. boosted its position in shares of Pfizer by 1.3% in the second quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company's stock valued at $736,000 after acquiring an additional 342 shares during the period. Sachetta LLC lifted its stake in Pfizer by 7.3% in the 2nd quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company's stock worth $140,000 after purchasing an additional 342 shares in the last quarter. Wells Trecaso Financial Group LLC grew its position in shares of Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock valued at $416,000 after purchasing an additional 350 shares in the last quarter. Ironvine Capital Partners LLC increased its holdings in shares of Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company's stock worth $470,000 after purchasing an additional 353 shares during the period. Finally, Secure Asset Management LLC raised its position in shares of Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company's stock worth $1,632,000 after buying an additional 353 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PFE shares. Daiwa America raised Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 31st. Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Finally, Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $32.92.

Pfizer Stock Down 0.6 %

Shares of NYSE PFE opened at $24.95 on Thursday. The company has a market cap of $141.36 billion, a price-to-earnings ratio of 33.71, a PEG ratio of 0.80 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm's fifty day moving average is $28.36 and its 200 day moving average is $28.61. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the prior year, the business posted ($0.17) earnings per share. Pfizer's revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.73%. Pfizer's dividend payout ratio (DPR) is presently 227.03%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.